UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

European journal of cancer (1990), 2009-01, Vol.45 (2), p.228-247

2009

Volltextzugriff (PDF)

84 The A-Z of Clinical Trials – Clinical Trial Design Incorporating Efficacy, Translational and Biomarker Endpoints

European journal of cancer (1990), 2012-07, Vol.48, p.S20-S20

Eisenhauer, E.A

2012

Volltextzugriff (PDF)

Evaluation of lymph nodes with RECIST 1.1

European journal of cancer (1990), 2009-01, Vol.45 (2), p.261-267

2009

Volltextzugriff (PDF)

Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199)

Gynecologic oncology, 2013-08, Vol.130 (2), p.269-274

2013

Volltextzugriff (PDF)

Real-world evidence in the treatment of ovarian cancer

Annals of oncology, 2017-11, Vol.28 (suppl_8), p.viii61-viii65

Eisenhauer, E A

2017

Volltextzugriff (PDF)

Lessons learned from independent central review

European journal of cancer (1990), 2009-01, Vol.45 (2), p.268-274

2009

Volltextzugriff (PDF)

First application of the Automated QUantitative Analysis (AQUA) technique to quantify PTEN protein expression in ovarian cancer: A correlative study of NCIC CTG OV.16

Gynecologic oncology, 2016-03, Vol.140 (3), p.486-493

2016

Volltextzugriff (PDF)

Phase I Clinical Trial Design in Cancer Drug Development

Journal of clinical oncology, 2000-02, Vol.18 (3), p.684-692

2000

Volltextzugriff (PDF)

Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients

Annals of oncology, 1997-10, Vol.8 (10), p.963-968

1997

Volltextzugriff (PDF)

54IN - Antiangiogenics in Ovarian Cancer: Where are We Now?

Annals of oncology, 2012-09, Vol.23, p.ix40-ix40

Eisenhauer, E.A.

2012

Volltextzugriff (PDF)

Antiangiogenics in Ovarian Cancer: Where are We Now?

Annals of oncology, 2012-09, Vol.23, p.ix40

Eisenhauer, E.A.

2012

Volltextzugriff (PDF)

Update in methodology and conduct of cancer clinical trials

European journal of cancer (1990), 2006-07, Vol.42 (10), p.1322-1330

2006

Volltextzugriff (PDF)

RECIST revisited: A review of validation studies on tumour assessment

European journal of cancer (1990), 2006-05, Vol.42 (8), p.1031-1039

2006

Volltextzugriff (PDF)

Early integration of palliative care into standard oncology care: evidence and overcoming barriers to implementation

Current oncology (Toronto), 2016-12, Vol.23 (6), p.374-377

2016

Volltextzugriff (PDF)

Optimal assessment of response in ovarian cancer

Annals of oncology, 2011-12, Vol.22 Suppl 8, p.viii49-viii51

Eisenhauer, E A

2011

Volltextzugriff (PDF)

OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer

Annals of oncology, 2018-02, Vol.29 (2), p.431-438

2018

Volltextzugriff (PDF)

11 New response evaluation criteria in solid tumors: RECIST GUIDELINE VERSION 1.1

European journal of cancer supplements, 2009, Vol.7 (2), p.5-5

2009

Volltextzugriff (PDF)

A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study

Annals of oncology, 2011-02, Vol.22 (2), p.335-340

2011

Volltextzugriff (PDF)

Phase I and II trials of novel anti-cancer agents: Endpoints, efficacy and existentialism

Annals of oncology, 1998-10, Vol.9 (10), p.1047-1052

Eisenhauer, E.A.

1998

Volltextzugriff (PDF)

A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150

Annals of oncology, 2007-01, Vol.18 (1), p.116-121

2007

Volltextzugriff (PDF)

A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas—NCIC-CTG IND 200

Annals of oncology, 2015-05, Vol.26 (5), p.973-981

2015

Volltextzugriff (PDF)

Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179)

Annals of oncology, 2012-01, Vol.23 (1), p.238-244

2012

Volltextzugriff (PDF)

Response evaluation: beyond RECIST

Annals of oncology, 2007-07, Vol.18 (suppl-9), p.ix29-ix32

Eisenhauer, EA

2007

Volltextzugriff (PDF)

Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study

Annals of oncology, 2011-11, Vol.22 (11), p.2403-2410

2011

Volltextzugriff (PDF)

MDICT Task Force: Methodology for the Development of Innovative Cancer Therapies

Annals of oncology, 2007-06, Vol.18, p.iv7

2007

Volltextzugriff (PDF)

1 – 25 von 62

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(62)
Mit Volltextzugriff
(62)

Publikationsform

Artikel
(62)

Sprache

Englisch
(62)

Erscheinungsjahr

n.n

Thema

Humans
(40)
Oncology
(40)
Life Sciences & Biomedicine
(39)
Science & Technology
(39)
Female
(31)
Biological And Medical Sciences
(23)
Medical Sciences
(23)
Pharmacology. Drug Treatments
(22)
Antineoplastic Agents
(19)
Antineoplastic Agents - Therapeutic Use
(17)
Ovarian Neoplasms - Drug Therapy
(14)
Middle Aged
(12)
Ovarian Cancer
(12)
Aged
(10)
Adult
(9)
Chemotherapy
(8)
Hematology, Oncology And Palliative Medicine
(8)
Male
(8)
Treatment Outcome
(8)
Tumors
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

84 The A-Z of Clinical Trials – Clinical Trial Design Incorporating Efficacy, Translational and Biomarker Endpoints

Evaluation of lymph nodes with RECIST 1.1

Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199)

Real-world evidence in the treatment of ovarian cancer

Lessons learned from independent central review

First application of the Automated QUantitative Analysis (AQUA) technique to quantify PTEN protein expression in ovarian cancer: A correlative study of NCIC CTG OV.16

Phase I Clinical Trial Design in Cancer Drug Development

Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients

54IN - Antiangiogenics in Ovarian Cancer: Where are We Now?

Antiangiogenics in Ovarian Cancer: Where are We Now?

Update in methodology and conduct of cancer clinical trials

RECIST revisited: A review of validation studies on tumour assessment

Early integration of palliative care into standard oncology care: evidence and overcoming barriers to implementation

Optimal assessment of response in ovarian cancer

OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer

11 New response evaluation criteria in solid tumors: RECIST GUIDELINE VERSION 1.1

A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study

Phase I and II trials of novel anti-cancer agents: Endpoints, efficacy and existentialism

A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150

A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas—NCIC-CTG IND 200

Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179)

Response evaluation: beyond RECIST

Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study

MDICT Task Force: Methodology for the Development of Innovative Cancer Therapies

Suchergebnisse filtern